medigraphic.com
Colegio de Medicina Interna de México.

2009, Número 3

<< Anterior Siguiente >>

Med Int Mex 2009; 25 (3)


Fibrosis nefrogénica sistémica

Bourlon CRA, Quiróz CÓ, Bourlon RC, Vera UR, Contreras ZK

Idioma: Español
Referencias bibliográficas: 28
Paginas: 210-216
Archivo PDF: 265.16 Kb.


RESUMEN

La fibrosis nefrogénica sistémica es una nueva enfermedad que se caracteriza por fibrosis tisular en pacientes con alteraciones de la función renal. Se asocia con exposición previa al medio de contraste con gadolíneo en estudios de resonancia magnética. La progresión de la enfermedad puede condicionar la muerte. Es importante que el personal de salud tenga conciencia de la posibilidad de esta enfermedad en pacientes con factores de riesgo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Issa N, Poggio ED, Fatica RA, Patel R, et al. Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI. Cleveland Clinic Journal of Medicine 2008;75(2):95-111.

  2. Cowper SE, Robin HS, Steinberg SM, Su LD, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.

  3. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660.

  4. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006;18:614.

  5. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadoliniumbased MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647.

  6. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis-setting the record straight. Semin Arthritis Rheum 2006;35:208.

  7. The International Center for Nephrogenic Fibrosing Dermopathy Research. http://www.icnfdr.org (Accessed January, 2008).

  8. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139:928.

  9. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148.

  10. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004;351:2219.

  11. Cowper SE, Bucala R, LeBoit PE. Case 35-2004: nephrogenic fibrosing dermopathy. N Engl J Med 2005;352:1723.

  12. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35:238.

  13. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents St. Louis, Missouri, 2002-2006. MMWR 2007;56:137.

  14. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21.

  15. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:710.

  16. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: A cause for concern. Semin Dial 2007;20:1.

  17. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264.

  18. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491.

  19. Saitoh T, Hayasaka K, Tanaka Y, et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006;24:445.

  20. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide- associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586.

  21. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383.

  22. Edsall LC, English JC, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004;31:247.

  23. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614–617.

  24. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569.

  25. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006;6:2212.

  26. Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000; 106:663.

  27. http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm

  28. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359.




2020     |     www.medigraphic.com